New Triple-Drug attack on tough liver cancer
NCT ID NCT06698250
Summary
This study is testing a new three-drug combination for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if adding a new drug called zanzalintinib to two existing immunotherapy drugs helps control the cancer better. The study will first find the safest dose and then see how well the combination works in about 40 participants who have not yet had other drug treatments for their advanced cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Neal Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mays Cancer Center, UT Health San Antonio
NOT_YET_RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.